Diffuse large B cell lymphoma: how can we cure more patients in 2012?

Area of Science:

• Hematology
• Oncology
• Medical Imaging

Background:

• Diffuse large B cell lymphoma (DLBCL) management requires updated strategies.
• The rituximab era has changed treatment paradigms for DLBCL.
• Primary refractory and relapsed disease remain significant challenges.

Purpose of the Study:

• To outline critical clinical issues in DLBCL management as of 2012.
• To discuss risk stratification methods for DLBCL patients.
• To evaluate the utility of interim PET-CT scans and high-dose therapy with ASCT.

Main Methods:

• Review of current clinical practices and literature in 2012.
• Focus on risk stratification tools.
• Analysis of interim PET-CT scan interpretation.
• Assessment of high-dose therapy and ASCT efficacy in the rituximab era.

Main Results:

• Risk stratification is crucial for tailoring DLBCL treatment.
• Interim PET-CT scans can guide therapy adjustments.
• High-dose therapy with ASCT shows potential in select relapsed/refractory DLBCL patients.

Conclusions:

• Optimized DLBCL management in 2012 involves integrated risk assessment and response-adapted strategies.
• Interim PET-CT and ASCT are important considerations for refractory/relapsed DLBCL.
• Continued research is needed to refine DLBCL treatment protocols.